tiprankstipranks
Circio Advances RNA Therapeutics and Cancer Vaccine
Company Announcements

Circio Advances RNA Therapeutics and Cancer Vaccine

Targovax ASA (GB:0RIS) has released an update.

Don't Miss our Black Friday Offers:

Circio Holding ASA has increased its share capital to NOK 27,264,865.20 following the conversion of convertible bonds by Atlas Special Opportunities, LLC. The biotechnology company is advancing its proprietary circVec technology for RNA therapeutics and is conducting clinical trials for its cancer vaccine, TG01, in the USA and Norway. These initiatives are supported by research grants, enabling cost-effective development with potential future benefits.

For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskCircio Holding ASA Unveils RNA Technology Updates
TipRanks European Auto-Generated NewsdeskCircio Holding ASA Issues Stock Options to Key Employees
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App